ASBP — Aspire Biopharma Holdings Balance Sheet
0.000.00%
Last trade - 00:00- $16.86m
- $25.13m
Annual balance sheet for Aspire Biopharma Holdings, fiscal year end - December 31st, millions except per share.
2020 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | |
| Standards: | — | USG | USG | USG |
| Status: | fx Preliminary | Final | Final | Final |
| Cash | ||||
| Cash and Short Term Investments | — | 0.497 | 0 | — |
| Net Total Receivables | — | — | — | 0.036 |
| Prepaid Expenses | ||||
| Total Other Current Assets | ||||
| Total Current Assets | — | 1.1 | 0.081 | 0.046 |
| Long Term Investments | ||||
| Other Long Term Assets | ||||
| Total Assets | — | 300 | 20 | 6.71 |
| Payable / Accrued | ||||
| Accrued Expenses | ||||
| Notes Payable / Short Term Debt | ||||
| Total Other Current Liabilities | ||||
| Total Current Liabilities | — | 0.303 | 0.403 | 15.6 |
| Total Long Term Debt | ||||
| Total Debt | ||||
| Total Other Liabilities | ||||
| Total Liabilities | — | 11.1 | 0.403 | 15.6 |
| Common Stock | ||||
| Additional Paid In Capital | ||||
| Retained Earnings (Accumulated Deficit) | ||||
| Total Equity | — | 289 | 19.6 | -8.9 |
| Total Liabilities & Shareholders' Equity | — | 300 | 20 | 6.71 |
| Total Common Shares Outstanding |